References
- Shaw EG, Debinski W, Robbins ME. Central nervous system tumors. In: Gunderson LL, Tepper JE, Editors. Clinical Radiation Oncology, 2nd ed. Philadelphia, PA, USA: Elsevier Churchill Livingstone; 2007:457-493.
- Siker ML, Donahue BR, Vogelbaum MA, Tome WA, Gilbert ML, Mehta MP. Primer intracranial neoplasms. In: Halperin EC, Perez CA, Brady LW, Editors. Principles and Practice of Radiation Oncology, 5th ed. Philadelphia, PA, USA: Wolters-Lippincott; 2008: 717-751.
- Stieber VW, McMullen KP, Munley MT, Shaw EG. Central nervous system tumors. In: Levitt SH, Purdy JA, Perez CA, Vijayakumar S, Editors. Technical Basis of Radiation Therapy, 4th ed. Berlin, Germany: Springer; 2006: 425-453.
- Donahue BR. Adult gliomas. In: Lu JJ, Brady LW, Editors. Radiation Oncology - An Evidence-Based Approach, 1st ed. Berlin, Germany: Springer; 2008: 483-501.
- Woo SY. Central nervous system. In: Cox JD, Ang KK, Editors. Radiation Oncology. Philadelphia, PA, USA: Mosby Elsevier; 2010: 835-875.
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(7): 277-300.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.
- Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010; 77(3): 670-676.
- Trivedi RN, Almeida KH, Fomsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005; 65(14): 6394-6400.
- Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995; 51: 167-223.
- Gerson SL. Clinical relevance of MGMT in the treatment of cancer.J Clin Oncol 2002;20:2388-99.
- Gerson SL, Trey JE, Miller K, Berger NA. Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986; 7(5): 745-49.
- Dumenco LL, Allay E, Norton K, Gerson SL. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science. 1993; 259(5092): 219-222.
- Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26(25): 4189-4199.
- Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997; 17(9): 5612-5619.
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003.
- Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009; 101(1): 124-131.
- Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glio-blastomas. Neurosurgery. 2009; 65(5): 866-875; discussion: 875.
- Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, et al. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol. 2012; 29(2): 1292-1296.
- Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19): 1350-1354.
- Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004; 10(15): 4933-4938.
- Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, et al. Comprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBM. PLoS One. 2011; 6(1): el6146.
- Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Mashhad MJ, Hassanian SM, et al.. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Cell Physiol. 2018; 233(1): 378-386.
- Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, et al. Prognostic value of 06-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. JNeurooncol. 2010; 97(3): 311-322.